juvenile arthritis

Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Humira approved for treating polyarticular juvenile idiopathic arthritis patients aged 2 and olderFDA has extended the indication for adalimumbab (Humira, AbbVie) to include the treatment of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) to reducing signs and symptoms in patients aged 2 years and older.
Juvenile idiopathic arthritis: Rethinking remissionJuvenile idiopathic arthritis (JIA) refers to a heterogenous group of all forms of chronic arthritis in childhood with no apparent cause that begins prior to age 16 years and lasts for more than 6 weeks.
FDA actions in brief